Sima Azish - Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
Mohammad Garakyaraghi - Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
Mehrbod Vakhshoori - Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
Maryam Heidarpour - Assistant Professor of Endocrinology, Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Mohaddeseh Behjati - Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
Kiyan Heshmat-Ghahdarijani - Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
Sepehr Omoomi - Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
Mohammad Fakhrolmobasheri - Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
Davood Shafie - Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
Nizal Sarrafzadegan - Professor, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

BACKGROUND: Garlic may have anti-oxidanmayti-hypertensive and anti-hyperlipidemic properties. However, the effects of its administration on cardiac function in heart failure (HF) patients impact require further investigation. We aimed to evaluate garlic prescription effects on cardiac outcomes and quality of life scores in Iranian HF patients.METHODS: From August to December ۲۰۲۰, a randomized, double-blind clinical trial was conducted. Individuals with heart failure (New York heart association (NYHA) functional class of II and III) referred to private clinics in Isfahan, Iran, were randomly assigned to intervention (n=۸۰) and control (n=۸۰) groups. They have received ۵۰۰ mg of odorless garlic tablets or the same shape and dosage of placebo twice daily for three months. Laboratory data, cardiac outcomes (end-diastolic diameter, ventricular septal thickness, NYHA functional class, left ventricular ejection fraction), quality of life score (Minnesota living with HF questionnaire), and the Modified Borg Scale (MBS) were all evaluated at the baseline and the end of the trial.RESULTS: The population’s mean age was ۵۸.۱±۱۳.۵ years (۵۵% males). Patients who consumed garlic had remarkably improved functional class compared to placebo takers and their baseline (NYHA practical class of II, ۷۹.۴% vs. ۵۰.۶%, P<۰.۰۰۱ and ۷۹.۴% vs. ۵۴%, P=۰.۰۰۶, respectively). MBS levels were significantly lower among garlic consumers (baseline: ۲.۵۲±۰.۵, after three months: ۲.۲±۱.۰۶, P= ۰.۰۴۰).CONCLUSIONS: Garlic administration may improve cardiac function and breathe in HF patients. Complementary research is necessary to confirm our findings.

Heart Failure, Garlic, Randomized Controlled Trial, Quality of Life